Literature DB >> 7608898

The serotonin 5-HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site.

K H Buchheit1, R Gamse, R Giger, D Hoyer, F Klein, E Klöppner, H J Pfannkuche, H Mattes.   

Abstract

The design and synthesis of a new class of potent and selective 5-HT4 receptor agonists containing an indole nucleus linked to a carbazimidamide are presented. A conformational study of the 5-HT4 receptor agonists serotonin and zacopride led to the identification of an initial pharmacophore and to the definition of a three-dimensional map of the 5-HT4 agonist recognition site. 1, a representative member of our new class of 5-HT4 receptor agonists, incorporates all reference structural features and matched perfectly with these models. 1 is a highly potent, full agonist at 5-HT4 receptors present in the isolated electrically stimulated guinea pig ileum preparation, with a pD2 value of 8.8, displaying selectivity (ranging from 40- to over 10,000-fold) versus other members of the serotonin receptor family.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7608898     DOI: 10.1021/jm00013a009

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle.

Authors:  N H Prins; J F Van Haselen; R A Lefebvre; M R Briejer; L M Akkermans; J A Schuurkes
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.

Authors:  S Appel-Dingemanse; M O Lemarechal; A Kumle; M Hubert; E Legangneux
Journal:  Br J Clin Pharmacol       Date:  1999-05       Impact factor: 4.335

3.  Panic Attack Precipitated by Tegaserod plus Fluoxetine.

Authors:  Ilker Tasci; Murat Gulsun
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 4.  Tegaserod.

Authors:  L J Scott; C M Perry
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 5.  Role of serotonin in Alzheimer's disease: a new therapeutic target?

Authors:  Werner J Geldenhuys; Cornelis J Van der Schyf
Journal:  CNS Drugs       Date:  2011-09-01       Impact factor: 5.749

6.  New insights into the human 5-HT4 receptor binding site: exploration of a hydrophobic pocket.

Authors:  Lucie Rivail; Mireille Giner; Monique Gastineau; Magali Berthouze; Jean-Louis Soulier; Rodolphe Fischmeister; Frank Lezoualc'h; Bernard Maigret; Sames Sicsic; Isabelle Berque-Bestel
Journal:  Br J Pharmacol       Date:  2004-09-06       Impact factor: 8.739

Review 7.  Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.

Authors:  Antona J Wagstaff; James E Frampton; Katherine F Croom
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 8.  Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.

Authors:  J Tack; M Camilleri; L Chang; W D Chey; J J Galligan; B E Lacy; S Müller-Lissner; E M M Quigley; J Schuurkes; J H De Maeyer; V Stanghellini
Journal:  Aliment Pharmacol Ther       Date:  2012-02-22       Impact factor: 8.171

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.